{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:30:27Z","timestamp":1792668627540,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,5,5]],"date-time":"2008-05-05T00:00:00Z","timestamp":1209945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>It has been recognized that cure is possible for human immunodeficiency virus (HIV)\u2010infected patients with Burkitt lymphoma\/leukemia (BL) if appropriate chemotherapy is used. The introduction of rituximab in BL therapeutic schemes has been scarcely explored. The outcome and toxicity of HIV\u2010positive patients with BL treated in a rituximab and intensive chemotherapy\u2010based trial was evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Thirty\u2010six consecutive patients, 15 to 55 years of age, diagnosed with advanced stage BL were recruited from July 2003 to August 2006, stratified according to HIV infection status and treated with 6 cycles of intensive chemotherapy including 8 doses of rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Nineteen of the patients (53%) were HIV\u2010infected. Their clinical characteristics were comparable to those of the HIV\u2010negative patients. Complete remission (CR) rates were 88% and 84%, respectively, for HIV\u2010negative and \u2010positive patients. Twenty\u2010seven patients (82% and 68%, respectively, for HIV\u2010negative and \u2010positive patients) completed the 6 protocol scheduled cycles. HIV\u2010infected patients presented higher incidences of grade 3\u20134 mucositis (27% vs 7% of cycles, <jats:italic>P<\/jats:italic> = .0005) and severe infectious episodes (26% vs 8%, <jats:italic>P<\/jats:italic> = .0025). However, there were no statistically significant differences in 2\u2010year overall survival (82%, 95% confidence interval [CI], 65%\u201399% and 73%, 95% CI, 54%\u201392%, respectively) or 2\u2010year disease\u2010free survival (93%, 95% CI, 82%\u201399% and 87%, 95% CI 72%\u201399%, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Intensive immunochemotherapy can be administered safely to patients with HIV infection. Despite a higher incidence of severe mucositis and infections the remission and survival rates are comparable to those observed in HIV\u2010negative patients. Cancer 2008. \u00a92008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23522","type":"journal-article","created":{"date-parts":[[2008,5,6]],"date-time":"2008-05-06T02:19:29Z","timestamp":1210040369000},"page":"117-125","source":"Crossref","is-referenced-by-count":100,"title":["High\u2010dose chemotherapy and immunotherapy in adult Burkitt lymphoma"],"prefix":"10.1002","volume":"113","author":[{"given":"Albert","family":"Oriol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep\u2010Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Bergua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Gim\u00e9nez Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salut","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u2010Jose","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Escoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus\u2010Maria","family":"Hernandez\u2010Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1736"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2339"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X"},{"key":"e_1_2_5_5_2","first-page":"445","article-title":"Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B\u2010cell lymphoma or leukemia. Results of the PETHEMA\u2010LAL3\/97 study","volume":"88","author":"Oriol A","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11628"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10365"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0989"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051771"},{"key":"e_1_2_5_10_2","first-page":"990","article-title":"Highly active antiretroviral therapy and outcome of AIDS\u2010related Burkitt's lymphoma or leukemia. Results of the PETHEMA\u2010LAL3\/97 study","volume":"90","author":"Oriol A","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"159a","DOI":"10.1182\/blood.V110.11.518.518","article-title":"High survival rate in adults Burkitt's lymphoma\/leukemia and diffuse large B\u2010cell lymphoma with mediastinal involvement","volume":"110","author":"Hoelzer D","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_15_2","volume-title":"ISCN: An International System for Human Cytogenetic Nomenclature","author":"Mittelman F","year":"1995"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.3.381"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J Roy Stat Soc Ser B."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.8.8"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92513-2"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.973"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-006-6314-5"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06943.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_5_26_2","first-page":"831a","article-title":"Long\u2010term outcome after hyper\u2010CVAD and rituximab chemoimmunotherapy for Burkitt or Burkitt\u2010like leukemia\/lymphoma and mature B\u2010cell acute lymphocytic leukemia","volume":"118","author":"Thomas DA","year":"2007","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23522","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:38:41Z","timestamp":1760305121000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23522"}},"subtitle":["Comparison of results in human immunodeficiency virus\u2010infected and noninfected patients"],"short-title":[],"issued":{"date-parts":[[2008,6,20]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1002\/cncr.23522"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23522","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,20]]}}}